On this page
India pharma market seen growing about 10% in FY27 as costs pressure margins
Our read
India pharma revenue growth holds near 10% in FY27, but earnings dispersion widens as branded chronic and GLP-1 exposure outperform while US-generics and cost-sensitive manufacturers face margin pressure.
For operators
Plan for roughly 10% FY27 domestic growth by prioritizing chronic, launch and GLP-1 portfolios while offsetting material, freight and logistics inflation through tighter sourcing and operating discipline.
Watch
Monthly domestic pharma sales growth, especially chronic, anti-diabetic, cardiac and metabolic therapy segments.
The report,
Ind-Ra expects India’s domestic pharma market to grow about 10% in FY27, supported by chronic therapies, new launches and GLP-1 adoption. Higher material, freight and logistics costs, weak US generics and regulatory scrutiny are expected to soften margins.
Reported figures
From the report. Source details below
| Industry sales growth in Q1 FY27: | 11.5% year-on-year |
|---|---|
| US revenues for 13 tracked companies: | down 8% year-on-year in Q1 FY27 |
| Q1 FY27 gross margin: | around 70% |
| Q1 FY27 EBITDA margin: | around 23% |
Why it matters to operators
India pharma’s resilient domestic demand supports growth visibility, but margin expectations should be tempered by input-cost inflation, softer US generics and heightened regulatory risk.
What to watch next
- GLP-1 product launches, affordability initiatives, prescription growth and supply availability in India.
- API, intermediates, packaging, fuel, freight and logistics-cost trends.
- Domestic price-control actions, NPPA decisions and companies' ability to implement price increases outside controlled categories.
- US generic price erosion, ANDA approval cadence, channel inventory trends and FDA inspection outcomes.
The counter-case
The case against this reading — not reported by the source.
A 10% FY27 growth forecast may overstate underlying demand if recent growth has been supported by price increases, channel restocking and a favorable therapy mix rather than sustained volume expansion. Domestic pricing controls, intensified competition in chronic therapies and lower-cost generic substitution could limit realization growth. GLP-1 adoption may remain niche because of affordability, supply constraints and limited reimbursement. Meanwhile, input and freight inflation may prove temporary or be offset by price hikes, procurement savings and currency moves, making the projected margin pressure less severe than implied. US generics weakness is also uneven across companies and may not materially affect domestically focused manufacturers.
The source
Published
First seen